130 related articles for article (PubMed ID: 38219000)
1. ASO Author Reflections: Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Apr; 31(4):2511-2512. PubMed ID: 38219000
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Integrating Multimodal Pain Management Protocols into ERAS for Patients Undergoing CRS-HIPEC.
Yue T; Sun B; Lee B
Ann Surg Oncol; 2024 Jul; 31(7):4741-4742. PubMed ID: 38483646
[No Abstract] [Full Text] [Related]
3. Beyond surgical excellence: Unveiling the role of intensive rehabilitation in RIOT for CRS and HIPEC.
Souadka A; El Ahmadi B
J Surg Oncol; 2023 Sep; 128(4):706-707. PubMed ID: 37345446
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Which is the Better Choice for Patients with PC Who Underwent Diaphragm Resection: HIPEC or HITAC.
Liu G; Li Y
Ann Surg Oncol; 2024 Feb; 31(2):1069-1070. PubMed ID: 37952219
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery.
Ghirardi V; Trozzi R; Scambia G; Fagotti A
Ann Surg Oncol; 2024 Jul; 31(7):4580-4581. PubMed ID: 38446331
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
Bansal VV; Mitchell O; Drazer MW; Kindler HL; Turaga KK
Ann Surg Oncol; 2024 Jun; 31(6):3785-3786. PubMed ID: 38502295
[No Abstract] [Full Text] [Related]
7. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
[TBL] [Abstract][Full Text] [Related]
8. Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Jan; 31(1):556-566. PubMed ID: 37940804
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
10. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
11. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
12. ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma.
Chouliaras K; Votanopoulos KI
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):770-771. PubMed ID: 30421064
[No Abstract] [Full Text] [Related]
13. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
14. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal mesothelioma in Sweden: A population-based study.
Cashin PH; Jansson Palmer G; Asplund D; Graf W; Syk I
Cancer Med; 2019 Oct; 8(14):6468-6475. PubMed ID: 31483564
[TBL] [Abstract][Full Text] [Related]
16. ASO Author Reflections: International Standardization of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocols-Malignant Peritoneal Mesothelioma as a Model.
Kepenekian V; Sgarbura O; Marchal F; Villeneuve L; Kusamura S; Deraco M
Ann Surg Oncol; 2023 Nov; 30(12):7858-7859. PubMed ID: 37626249
[No Abstract] [Full Text] [Related]
17. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
[TBL] [Abstract][Full Text] [Related]
18. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
Valenzuela CD; Solsky IB; Erali RA; Forsythe SD; Mangieri CW; Mainali BB; Russell G; Perry KC; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 May; 30(5):2666-2675. PubMed ID: 36754945
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
